最新发布

🎥 Inside Faraday Earth’s bid to make cheap green ammonia without Haber-Bosch

[Disclosure: AgFunderNews’ parent company AgFunder is an investor in Faraday Earth] Can a container-sized plasma reactor…

氟烯线砜靶向杀灭松材线虫机制突破,山东农大团队首次揭示潜在靶标BxALDH

世界农化网中文网报道:由松材线虫(Bursaphelenchus xylophilus)引发的松材线虫病是严重威胁松林工业用材林产业与生态安全的重大生物灾害。注干防治为主要防治手段,目前十六元大环内酯类杀线剂如甲维盐等为主要注干药剂,但长期使用单一药剂易诱发线虫产生抗药性,且部分杀线剂存在水溶性差、树体传导速率慢和稳定性差等问题。因此,开发新型高效、机制清晰和环境友好的新型杀线剂十分重要和必要。

Isomorphic megadeal lifts UK biotech funding to five-year high

Zoom in: Venture capital accounted for £2.05 billion of the total, according to the BioIndustry Association’s latest quarterly financing report.

Genetic Study Links Excessive Sweating to Neurological Dysfunction

Data from a new study suggest that a form of hyperhidrosis, or excessive sweating, may be due to genetic mutations that result in the overstimulation of the nerves that control the sweat glands. These findings, which are reported in Science Advances , could open a door to targeted treatments for the condition using existing medicines. Full details of the findings are provided in the paper titled “ A neurocutaneous NaV1.8 channelopathy underlies a genetic subtype of primary idiopathic hyperhidrosis .” The international study is led by scientists at Vrije Universiteit Brussel.

FAO Launches CropSuit App to Help Farmers Grow the Right Crops in the Right Places

Farmers, extension workers and governments now have a powerful new tool to help identify the crops best suited to specific parcels of land, enabling more efficient use of resources and greater resilience to climate change.

🎥 Can non thermal plasma seed treatment move from lab curiosity to broadacre reality?

[Disclosure: AgFunderNews’ parent company AgFunder is an investor in Sylvarum] Using non-thermal plasma or high voltage …

World Food Safety Day / From Burden Estimates To Solutions: Damascus Marks The Day

July 2026, Rome: Under the theme “From Burden Estimates to Solutions: Towards Safe Food Everywhere”, and on the occasion…

KRAS-Targeted Vaccine Crosses First Clinical Milestone in Pancreatic Cancer Prevention

A vaccine to prevent pancreatic cancer, targeting common KRAS mutations, was found to be safe and stimulated KRAS-specific T-cell responses in 90% of study participants who were at high risk of developing pancreatic ductal adenocarcinoma (PDAC), according to Phase I clinical trial results. After a median follow-up of 16.5 months, none of the participants developed pancreatic cancer, and some of the precancerous lesions shrank or stopped growing. The study represents the first proof of concept for the use of vaccines for interception of pancreatic cancer in human patients.

Orakl takes on four Sanofi cancer assets

Why it matters: The agreements give Orakl a potentially important pharmaceutical validation project for O-Predict, its system for forecasting clinical response and helping drug developers choose patient groups, combinations and trial strategies.

Mission Therapeutics refocuses on CNS and sells $292M kidney drug to Dimerix

Why it matters: The divestment gives Cambridge-based Mission non-dilutive funding for MTX325, its remaining clinical-stage USP30 inhibitor, while handing the kidney programme to a company already running a global Phase 3 renal trial.